Our findings warrant a need for further research, including randomized controlled trials, to evaluate whether water-induced reduction of vasopressin is able to reduce the risk of developing diseases that appear to be associated with higher plasma concentration of copeptin, such as diabetes mellitus, chronic kidney disease, and cardiovascular disease. The gene discussed is AVP; the disease is chronic kidney disease.